صﺧﻠﻣ :ﺔﻣﺎﻋ تﺎﻣوﻠﻌﻣ ﺔﺿرﻋ مﮭﻠﻌﺟﺗ ﺔﯾﺑﻠﺳ ﺔﯾﺿﯾأ ﺔﻐﯾﺻ مﮭﯾدﻟ ﺔطرﻔﻣﻟا ﺔﻧﻣﺳﻟا نﻣ نوﻧﺎﻌﯾ نﯾذﻟا صﺎﺧﺷﻷا لﻛ سﯾﻟ BioSHaRE-فدﮭﯾ .ﺔﯾوﻣدﻟا ﺔﯾﻋوﻷاو بﻠﻘﻟا ضارﻣأ وأ 2 عوﻧﻟا نﻣ يرﻛﺳﻟا ضرﻣﺑ ﺔﺑﺎﺻﻺﻟ لﻣاوﻋ نﻋ تﺎﻧﺎﯾﺑ مادﺧﺗﺳﺎﺑ (ﺔﯾﺣﺻﻟا) ﺔﻧﻣﺳﻟا بﻗاوﻌﺑ مﺎﻣﻟﻹا ﻰﻟإ ﺔطرﻔﻣﻟا ﺔﻧﻣﺳﻠﻟ ﻲﺣﺻﻟا عورﺷﻣﻟاEU وھ ﺔﺳاردﻟا هذھ نﻣ فدﮭﻟا نﺎﻛو .قﺎطﻧﻟا ﺔﻌﺳاو ﺔﯾﺑارﺗﻷا تﺎﺳاردﻟا نﻣ دﯾدﻌﻟا رﺑﻋ ﺔﯾرھﺎظﻟا طﺎﻣﻧﻷاو رطﺧﻟا ﻲﻓ (MHO) ﺔﯾﺿﯾﻷا ﺔﯾﺣﺎﻧﻟا نﻣ ﺔﯾﺣﺻﻟا ﺔﻧﻣﺳﻟاو (MetS) ﻲﺋاذﻐﻟا لﯾﺛﻣﺗﻟا ﺔﻣزﻼﺗﻣو ﺔﻧﻣﺳﻟا رﺎﺷﺗﻧا فﺻو .ﺔﻛرﺎﺷﻣ تﺎﺳارد رﺷﻋ

1. :‫ﺑﺎ‬ ‫ﻓﻲوروأ‬ ‫ﻷﯾﺿﯾﺔ‬ ‫ﻟﻧﺎﺣﯾﺔا‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫ﻟﻐاذﺋﻲاو‬ ‫ا‬‫ل‬ ‫ﻟﺗﻣﺛﯾ‬ ‫ﻣﺗﻼزﻣﺔا‬ ‫اﻧﺗﺷﺎر‬
‫ة‬‫ر‬ ‫ﻛﺑﯾ‬ ‫ﺑﯾﺔ‬ ‫ا‬‫ر‬ ‫ﺗ‬ ‫أ‬‫ت‬ ‫ﺳﺎ‬ ‫ا‬‫ر‬‫د‬‫ر‬ ‫ﻟﻌﺷ‬ ‫ﺗﻌﺎوﻧﻲ‬ ‫ﺗﺣﻠﯾل‬
‫ﻣﻠﺧص‬
:‫ﻋﺎﻣﺔ‬ ‫ﻣﻌﻠوﻣﺎت‬
‫ﻋرﺿﺔ‬ ‫ﺗﺟﻌﻠﮭم‬ ‫ﺳﻠﺑﯾﺔ‬ ‫ﯾﺿﯾﺔ‬ ‫ﺻﯾﻐﺔأ‬ ‫ﻟدﯾﮭم‬ ‫ﻟﻣﻔطرﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﯾﻌﺎﻧنو‬ ‫ﻟذﯾن‬ ‫ا‬‫ص‬ ‫ﻷﺷﺧﺎ‬ ‫ا‬‫ل‬ ‫ﻛ‬ ‫ﻟﯾس‬ BioSHaRE-‫ﯾﮭفد‬ .‫ﻟدﻣوﯾﺔ‬ ‫ﻷوﻋﯾﺔا‬ ‫او‬‫ب‬ ‫ﻟﻘﻠ‬ ‫ا‬‫ضار‬ ‫ﻣ‬ ‫أ‬‫وأ‬ 2 ‫ﻟﻧعو‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﺳﻛير‬ ‫ا‬
‫ﺑﻣضر‬ ‫ﻟﻺﺻﺎﺑﺔ‬
‫ﻋاوﻣل‬ ‫ﻋن‬ ‫ﺑﯾﺎﻧﺎت‬ ‫ﺑﺎﺳﺗﺧماد‬ (‫)اﻟﺻﺣﯾﺔ‬ ‫ﻟﺳﻣﻧﺔ‬ ‫ا‬‫ب‬ ‫ﺑﻌاوﻗ‬ ‫ﻹﻟﻣﺎم‬ ‫ﻟﻰا‬ ‫ﻟﻣﻔطرﺔإ‬ ‫ﻟﻠﺳﻣﻧﺔا‬ ‫ﻟﺻﺣﻲ‬ ‫ا‬‫عور‬ ‫اﻟﻣﺷ‬EU ‫ﻟاردﺳﺔوھ‬ ‫ا‬‫ھذھ‬‫ن‬ ‫ﻣ‬ ‫ﻟﮭفد‬ ‫ا‬‫ن‬ ‫ﻛﺎ‬ ‫ﻟﻧطﺎق.و‬ ‫ﺳﻌﺔا‬ ‫ﻷﺗارﺑﯾﺔاو‬ ‫ا‬‫ت‬ ‫ﻟاردﺳﺎ‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﻌدﯾد‬ ‫ا‬
‫ﻋﺑر‬ ‫ﻟظﺎرھﯾﺔ‬ ‫ا‬‫ط‬ ‫ﻷﻧﻣﺎ‬ ‫او‬‫رط‬ ‫ﻟﺧ‬ ‫ﻓﻲا‬ (MHO) ‫ﻷﯾﺿﯾﺔ‬ ‫ﻟﻧﺎﺣﯾﺔا‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫(او‬MetS) ‫ﻟﻐاذﺋﻲ‬ ‫ا‬‫ل‬ ‫ﻟﺗﻣﺛﯾ‬ ‫ﻣﺗﻼزﻣﺔا‬ ‫ﻟﺳﻣﻧﺔو‬ ‫ا‬‫ر‬ ‫ﻧﺗﺷﺎ‬ ‫ا‬‫ف‬ ‫وﺻ‬
.‫ﻣﺷﺎرﻛﺔ‬ ‫ﺳﺎت‬ ‫ارد‬‫ر‬ ‫ﻋﺷ‬
:‫ﻷﺳﺎﻟﯾب‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﻣﺷﺎرﻛﯾن‬ ‫ﺟﻣﯾﻊا‬ ‫ﻛﺎن‬ ‫ﻣﻧﺳق.و‬ ‫ﺷﻛل‬ ‫ﻟﻰ‬ ‫ﻟﻣﺣوﻟﺔإ‬ ‫ا‬‫ت‬ ‫ﻟﺑﯾﺎﻧﺎ‬ ‫ا‬‫ماد‬ ‫ﺑﺎﺳﺗﺧ‬ ،‫ناد‬ ‫ﺑﻠ‬ ‫ﺳﺑﻊ‬ ‫ﻓﻲ‬
‫ﻣﺧﺗﻠﻔﺔ‬ ‫ﻓﺋﺎت‬ ‫ﻋﺷر‬ ‫ﺑﯾن‬ ‫ﻟﺟﻣﻊ‬ ‫ا‬‫م‬ ‫ﺗ‬ ‫ﻗﯾﺎس‬ ‫ﻟﺑﺷرﯾﺔو‬ ‫ا‬‫ت‬ ‫ﻟﻘﯾﺎﺳﺎ‬ ‫ا‬‫س‬ ‫ﻟﻘﯾﺎ‬ ‫ﻟﺳرﯾير‬ ‫ا‬‫ص‬ ‫ﻟﻔﺣ‬ ‫ﻓﻲا‬ ‫ﺷﺎرﻛاو‬ ‫ﻗد‬ ‫ﻋﺎﻣﺎ.و‬ 18-80 ‫ﺑﯾن‬ ‫ﻣﺎ‬ ‫ﻋﻣمھر‬ ‫ﯾﺗحوار‬ ،‫ﺑﻲ‬ ‫وروأ‬‫ل‬ ‫ﺻ‬ ‫ﻟﻐاذﺋﻲأ‬ ‫ا‬‫ل‬ ‫ﻟﺗﻣﺛﯾ‬ ‫ﻣﺗﻼزﻣﺔا‬ ‫ﺟدو‬ ‫و‬‫م‬ ‫ﺗﻘﯾﯾ‬ ‫ﺗم‬ ‫ﻗد‬ ‫و‬
.‫ﻟﺟﻠوﻛزو‬ ‫او‬‫نوھد‬ ‫ﻟ‬ ‫ا‬‫ل‬ ‫ﻟﺗﺣﻠﯾ‬ ‫ﻟمد‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻋﯾﻧﺎت‬ ‫ﺳﺣب‬ ‫ﺗم‬ ‫ﻗد‬ ‫ﻟمد.و‬ ‫ا‬‫ط‬ ‫ﺿﻐ‬
2001 NCEP ‫ﻣﻌﺎﯾﯾر‬ ‫ﻟﻰ‬ ‫إ‬‫اد‬ ‫ﺳﺗﻧﺎ‬ ‫ﻣرﺑﻊ(ا‬ ‫ﻣﺗر‬ / ‫ﻛﻎ‬ ≥ 30 ‫ﻟﺟﺳم‬ ‫ﻛﺗﻠﺔا‬ ‫)ﻣؤﺷر‬ ‫ﻟﺳﻣﻧﺔ‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﯾﻌﺎﻧنو‬ ‫ﻟذﯾن‬ ‫ﻓﻲا‬ (MetS) ‫ﻟﻧﺎﺣﯾﺔ‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫ا‬‫ف‬ ‫ﺗﻌرﯾ‬ ‫ﺗم‬ ‫ﻗد‬ ‫ﻛﺎن‬ ‫ً.و‬ ‫ﺗﺷادد‬ ‫ﻗل‬ ‫أ‬‫ر‬ ‫ﻣﻌﺎﯾﯾ‬ ‫ﻣن‬ ‫ﻣﻌدﻟﺔ‬
‫ﻣﺟﻣوﻋﺔ‬ ‫ﻋن‬ ‫ﻓﺿﻼ‬ ،ATP III criteria ‫ﺳﺎﺑق‬ ‫ﺗﺷﺧﯾص‬ ‫ﻻ‬ ‫و‬، (MetS) ‫ﻟﻐاذﺋﻲ‬ ‫ا‬‫ل‬ ‫ﻟﺗﻣﺛﯾ‬ ‫ﻣﺗﻼزﻣﺔا‬ ‫ﻣﻛوﻧﺎت‬ ‫ﻣن‬ ‫يأ‬‫ل‬ ‫ﺗﺷﻣ‬ ‫ﻻ‬ ‫ﻟﺗﻲ‬ ‫ا‬، ‫ﻟﺳﻣﻧﺔ‬ ‫ﺑﺄﻧﮭﺎا‬ (MHO) ‫اﻷﯾﺿﯾﺔ‬
.‫ﻟدﻣوﯾﺔ‬ ‫ﻷوﻋﯾﺔا‬ ‫او‬‫ب‬ ‫ﻟﻘﻠ‬ ‫ا‬‫ضار‬ ‫ﻷﻣ‬

2. :‫اﻟﻧﺗﺎﺋﺞ‬
16,612 ‫ﺟﻼو‬ ‫)564,11ر‬ ‫ﻟﻣﻔطرﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﯾﻌﺎﻧنو‬ ‫ﻣﻧﮭم‬ ٪17 ‫؛‬‫ادر‬ ‫ﻓ‬ 163,517 ‫ﻋن‬ ‫ﺑﯾﺎﻧﺎت‬ ‫ﻣﺗوﻓار‬ ‫ﻛﺎن‬ ‫و‬KORA ‫ﻣﺟﻣوﻋﺔ‬ ‫ﻓﻲ‬ ٪26.3 ‫ﻟﻰ‬ ‫ﻹﯾطﺎﻟﯾﺔإ‬ ‫ا‬CHRIS ‫ﻣﺟﻣوﻋﺔ‬ ‫ﻓﻲ‬ ٪11.6 ‫ﻣن‬
‫ﻟﺳﻣﻧﺔ‬ ‫ا‬‫ر‬ ‫ﻧﺗﺷﺎ‬ ‫ا‬‫تو‬ ‫ﺗﻔﺎ‬ ‫ﻗد‬ ‫ﻣةأر(.و‬ ‫ا‬‫ل‬ ‫ﻟﺗﻣﺛﯾ‬ ‫ﻣﺗﻼزﻣﺔا‬ ‫ﻣﻊ‬ ‫ﻟﻣﻔطرﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﯾﻌﺎﻧنو‬ ‫ﻟذﯾن‬ ‫ا‬‫ص‬ ‫ﻷﺷﺧﺎ‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﻣﻌﯾﺎير‬ ‫ا‬‫ر‬ ‫ﻟﻌﻣ‬ ‫ﻧﺳﺑﺔا‬ ‫ﺗوارﺣت‬ .‫اﻷﻟﻣﺎﻧﯾﺔ‬
‫ﻓﻲ‬ ‫و‬، Health2000 ‫ﻟﻔﻧﻠﻧدﯾﺔ‬ ‫ﻟﻣﺟﻣوﻋﺔا‬ ‫ﻓﻲا‬ ٪65 ‫ﻟﻰ‬ ‫إ‬CHRIS ‫ﻓﻲ‬ ٪24 ‫ﻣن‬ ‫ﻟﻧﺳﺎء‬ ‫ﻓﻲا‬ (MetS) ‫ﻟﻐاذﺋﻲ‬ ‫ا‬‫ل‬ ‫ﻟﻌﺎﻣ‬ ‫ا‬‫مد‬ ‫ﻟ‬ ‫ا‬‫ط‬ ‫ﺿﻐ‬ ‫ﺗﻔﺎع‬ ‫ﻣﻊرا‬ ،DILGOM ‫ﻟﻔﻧﻠﻧدﯾﺔ‬ ‫ﻟﻣﺟﻣوﻋﺔا‬ ‫ﻓﻲا‬ ٪78 ‫ﻟﻰ‬ ‫إ‬
CHRIS ‫ﻓﻲ‬ ٪43 ‫ﻣن‬ ‫اﻟرﺟﺎل‬
‫ﻣن‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ﻟﻠﺳﻣﻧﺔا‬ ‫ﻟﻣوﺣد‬ ‫ا‬‫ر‬ ‫ﻻﻧﺗﺷﺎ‬ ‫ا‬‫لد‬ ‫ﻣﻌ‬ ‫ﺗﻔﺎتو‬ ‫ﻗد‬ ‫ﻟﻐاذﺋﻲ.و‬ ‫ا‬‫ل‬ ‫ﻟﺗﻣﺛﯾ‬ ‫ﻣﺗﻼزﻣﺔا‬ ‫ﻧﺗﺷﺎر‬ ‫ﻟﻰا‬ ‫إ‬‫يدؤ‬ ‫ﯾ‬ ‫ﻟيذ‬ ‫ﺣودﺛﺎا‬ ‫ﻷﻛﺛر‬ ‫ﻓﻲا‬ ‫و‬، ‫ﻟﺳﺎرﯾﺔ‬ ‫ا‬‫ر‬ ‫ﻏﯾ‬ ‫ﻷﻣضار‬ ‫ﻓﻲا‬ ٪28 ‫ﻟﻰ‬ ‫إ‬Health2000 ‫ﻓﻲ‬ ٪7 ‫ﻣن‬ ‫ﻟﻧﺳﺎء‬ ‫ﻓﻲا‬
(MHO) ‫ﻷﯾﺿﯾﺔ‬ ‫ﻟﻧﺎﺣﯾﺔا‬ ‫ا‬‫ن‬ ‫ﻣ‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ﻟﺳﻣﻧﺔا‬ ‫ا‬‫ت‬ ‫ﻛﺎﻧ‬ ‫.و‬CHRIS ‫ﻣﺟﻣوﻋﺔ‬ ‫ﻓﻲ‬ ٪19 ‫ﻟﻰ‬ ‫إ‬DILGOM ‫ﯾﻠﻐمو‬ ‫ﻣﺟﻣوﻋﺔد‬ ‫ﻓﻲ‬ ٪2‫ﻣن‬ ‫اﻟرﺟﺎل‬
.‫ﻟﺟﻧﺳﯾن‬ ‫ﻛﻼا‬ ‫ﻓﻲ‬ ‫ﻟﻌﻣر‬ ‫ا‬‫مد‬ ‫ﺗﻘ‬ ‫ﻣﻊ‬ ‫ﻧﺧﻔﺿت‬ ‫او‬،‫ل‬ ‫ﻟرﺟﺎ‬ ‫ا‬‫ىد‬ ‫ﻟ‬ ‫ﻣﻧﮭﺎ‬ ‫ﻟﻧﺳﺎء‬ ‫ا‬‫ىد‬ ‫ﻟ‬ ‫ﻧﺗﺷﺎار‬ ‫ا‬‫ر‬ ‫أﻛﺛ‬
(MHO)‫ﻷﯾﺿﯾﺔ‬ ‫اﻟﻧﺎﺣﯾﺔا‬
:‫اﻻﺳﺗﻧﺗﺎﺟﺎت‬
‫ﺗﺣدد‬ ‫ﻟﺗﻲ‬ ‫ﻟرﺋﯾﺳﯾﺔا‬ ‫ا‬‫ص‬ ‫ﻟﺧﺻﺎﺋ‬ ‫ﻣﻘﺎرﻧﺔا‬ ‫ﻋﻠﻰ‬ ‫ﻗﺎارد‬ BioSHaRE-EU ‫ﻻﺗﺣﺎد‬ ‫ا‬‫ن‬ ‫ﻛﺎ‬ ،‫ةد‬ ‫ﺷدﯾ‬ ‫ﻣءاوﻣﺔ‬ ‫ﻋﻣﻠﯾﺔ‬ ‫ﺧﻼل‬ ‫ﻣن‬ ‫ﻟﺳﻣﻧﺔ‬ ‫ا‬‫ر‬ ‫ﻧﺗﺷﺎ‬ ‫ﻓﻲا‬ ‫ﻛﺑﯾر‬ ‫ﺗﺑﺎﯾن‬ ‫ﻧﺎك‬ ‫ﺗارﺑﯾﺔ.ھ‬ ‫أ‬‫ت‬ ‫ﺳﺎ‬ ‫ارد‬‫ر‬ ‫ﻋﺷ‬ ‫ﻋﺑر‬ ‫ﻷﯾﺿﯾﺔ‬ ‫ﻟﻧﺎﺣﯾﺔا‬ ‫ا‬
‫ﻣن‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ﻟﻠﺳﻣﻧﺔا‬ ‫ﻟظﺎيرھ‬ ‫ا‬‫ط‬ ‫ﻟﻧﻣ‬ ‫ا‬‫ط‬ ‫ﻟﻧﻣ‬ ‫ا‬‫اذھ‬‫ف‬ ‫ﻟﺗﺻﻧﯾ‬ ‫ﻣوﺣةد‬ ‫ﻣﻌﺎﯾﯾر‬ ‫ﺳﺗﺧماد‬ ‫ا‬‫م‬ ‫ﺗ‬ ‫ﻋﻧدﻣﺎ‬ ‫ﺣﺗﻰ‬ ،‫م‬ ‫ﺳﺗﮭ‬ ‫ارد‬‫م‬ ‫ﺗ‬ ‫ﻟذﯾن‬ ‫ا‬‫ن‬ ‫ﻷوروﺑﯾﯾ‬ ‫ا‬‫ن‬ ‫ﻟﺳﻛﺎ‬ ‫ا‬‫ف‬ ‫ﻣﺧﺗﻠ‬ ‫ﻋﺑر‬ ‫ﻟﺻﺣﯾﺔ‬ ‫ا‬‫يرھ‬ ‫اﻟظﺎ‬
-------------------------
‫ﺗرﺟﻣﺔاذھ‬ ‫ﺟرﯾت‬ ‫أ‬‫د‬ ‫ﻗ‬ ‫ﻹﻧﺟﻠﯾزﯾﺔ.و‬ ‫ا‬‫ر‬ ‫ﻏﯾ‬ ‫ﻟطﺑﯾﺔ‬ ‫ا‬‫ثو‬ ‫ﻟﺑﺣ‬ ‫ا‬‫ت‬ ‫ﻟﻣﻘﺎﻻ‬ ‫ﻟﻌﺎﻟﻣﯾﺔ‬ ‫ﻟؤرﯾﺔا‬ ‫ا‬‫م‬ ‫ﻟﻔﮭ‬ ‫ﺗﺟرﺑﺔ‬ ‫ُﺟير‬‫ﻧ‬ ،‫ﻟطﺑﯾﺔ‬ ‫ا‬‫ت‬ ‫ﻟﻣﻛﺗﺑﺎ‬ ‫ا‬‫ء‬ ‫ﻣﻧﺎ‬ ‫أ‬‫ن‬ ‫ﻧﺣ‬ ‫ﻧﺎ‬ ‫ﻟﻠﺟﻣﯾﻊھ‬ ‫ﻟﻣﺗﺎح‬ ‫ا‬‫ل‬ ‫ﻟﻣﻘﺎ‬ ‫ﻟﻰا‬ ‫إ‬‫ط‬ ‫ﺑ‬ ‫ارو‬PubMed ‫ﺑﺑﻣد‬ ‫ﻗﺗﺑﺎس‬ ‫ﻋﻠﻰا‬ ‫ﻹطﻼع‬ ‫ا‬‫ن‬ ‫ﯾﻣﻛ‬ ‫و‬
.‫ﻣﻌﺗﻣد‬ ‫ﻣﺗرﺟم‬ ‫ﺑاوﺳطﺔ‬ ‫اﻟﻣﻠﺧص‬
‫ﻟﻣﺷعور‬ ‫ﻋﻠﻰا‬ ‫ﺗﻌﻠﯾﻘﺎﺗك‬ ‫ﺿﺎﻓﺔ‬ ‫ﻓﻲإ‬ ‫ﺗﺗددر‬ ‫.ﻻ‬ https://www.ncbi.nlm.nih.gov/pubmed/?term=24484869
.‫ﻷﺻﻠﯾﺔ‬ ‫ﻟﻠﻐﺔا‬ ‫ا‬‫نو‬ ‫ﯾﺗﻛﻠﻣ‬ ‫َﻣن‬ ‫ِﻣ‬ ‫ﻛﻧت‬ ‫ﻟﺗرﺟﻣﺔاذإ‬ ‫ا‬‫ةدو‬ ‫ﺟ‬ ‫ﻋﻠﻰ‬ ‫و‬،‫ه‬ ‫دأﻧﺎ‬
.‫ﻛوﻟودارو‬ ‫ﺟﺎﻣﻌﺔ‬ ،‫ﻟﺻﺣﯾﺔ‬ ‫ا‬‫مو‬ ‫ﻟﻌﻠ‬ ‫ﻣﻛﺗﺑﺔا‬ ،‫ﺑﻲ‬ ‫ﻧﺎآ‬ ‫ادو‬‫ر‬ ‫ﻓﻛ‬ ‫وھ‬‫ن‬‫ﺎﯾﻠﯾﻟ‬ --

3. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of
ten large cohort studies
Abstract
BACKGROUND:
Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2 diabetes or
cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the consequences of
(healthy) obesity using data on risk factors and phenotypes across several large-scale cohort studies. Aim of this
study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically healthy obesity
(MHO) in ten participating studies.
METHODS:
Ten different cohorts in seven countries were combined, using data transformed into a harmonized format. All
participants were of European origin, with age 18-80 years. They had participated in a clinical examination for
anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of lipids and
glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m2) based on the 2001 NCEP ATP III
criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the MetS
components, and no previous diagnosis of cardiovascular disease.

4. RESULTS:
Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence of obesity
varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized percentage of
obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort, and in men from
43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently occurring factor
contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO varied in women
from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was more prevalent in
women than in men, and decreased with age in both sexes.
CONCLUSIONS:
Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key characteristics defining
the metabolically healthy obese phenotype across ten cohort studies. There is considerable variability in the prevalence
of healthy obesity across the different European populations studied, even when unified criteria were used to classify this
phenotype.
___________________________
We are medical librarians conducting an experiment to understand the global visibility of non-English medical research
articles. The translation for this abstract was performed by a certified translator. The PubMed citation and link to the
whole open access article can be found here https://www.ncbi.nlm.nih.gov/pubmed/?term=24484869. Please feel free
to add your comments below on the project and, if you are a native-speaker, on the quality of the translation.
--Lilian Hoffecker and Dana Abbey, Health Sciences Library, University of Colorado.